Skip to main content
Erschienen in: Annals of Hematology 1/2021

12.09.2020 | COVID-19 | Original Article Zur Zeit gratis

Prognostic significance of hemoglobin level and autoimmune hemolytic anemia in SARS-CoV-2 infection

verfasst von: Abdulrahman A. Algassim, Assem A. Elghazaly, Abdulrahman S. Alnahdi, Owais M. Mohammed-Rahim, Abdulaziz G. Alanazi, Nawaf A. Aldhuwayhi, Mashael M. Alanazi, Mohammed F. Almutairi, Ibrahim M. Aldeailej, Najeeb A. Kamli, Mahmoud D. Aljurf

Erschienen in: Annals of Hematology | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Higher levels of D-dimer, LDH, and ferritin, all have been associated with the poor prognosis of COVID-19. In a disease where there are acute inflammation and compromised oxygenation, we investigated the impact of initial hemoglobin (Hgb) levels at Emergency Department (ED) triage on the severity and the clinical course of COVID-19. We conducted a cross-sectional study on 601 COVID-19 patients in a COVID-19 national referral center between 13 and 27 June 2020. All adult patients presented at our hospital that required admission or hotel isolation were included in this study. Patients admitted to the intensive care unit (ICU) had a lower initial Hgb than those admitted outside the ICU (12.84 g/dL vs. 13.31 g/dL, p = 0.026) and over the course of admission; the prevalence of anemia (Hgb < 12.5 g/dL) was 65% in patients admitted to ICU, whereas it was only 43% in non-ICU patients (odds ratio of 2.464, 95% CI 1.71–3.52). Anemic ICU patients had a higher mortality compared with non-anemic ICU patients (hazard ratio = 1.88, log-rank p = 0.0104). A direct agglutination test (DAT) for all anemic patients showed that 14.7% of ICU patients and 9% of non-ICU patients had autoimmune hemolytic anemia (AIHA). AIHA patients had significantly longer length of hospital stay compared with anemic patients without AIHA (17.1 days vs. 14.08 days, p = 0.034). Lower Hgb level at hospital presentation could be a potential surrogate for COVID-19 severity.
Literatur
1.
Zurück zum Zitat Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395(10223):497–506CrossRef Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395(10223):497–506CrossRef
2.
Zurück zum Zitat Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z (2020) Clinical Characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 323:1061CrossRef Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z (2020) Clinical Characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 323:1061CrossRef
3.
Zurück zum Zitat Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, Bikdeli B, Ahluwalia N, Ausiello JC, Wan EY, Freedberg DE, Kirtane AJ, Parikh SA, Maurer MS, Nordvig AS, Accili D, Bathon JM, Mohan S, Bauer KA, Leon MB, Krumholz HM, Uriel N, Mehra MR, Elkind MSV, Stone GW, Schwartz A, Ho DD, Bilezikian JP, Landry DW (2020) Extrapulmonary manifestations of COVID-19. Nat Med 26(7):1017–1032CrossRef Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, Bikdeli B, Ahluwalia N, Ausiello JC, Wan EY, Freedberg DE, Kirtane AJ, Parikh SA, Maurer MS, Nordvig AS, Accili D, Bathon JM, Mohan S, Bauer KA, Leon MB, Krumholz HM, Uriel N, Mehra MR, Elkind MSV, Stone GW, Schwartz A, Ho DD, Bilezikian JP, Landry DW (2020) Extrapulmonary manifestations of COVID-19. Nat Med 26(7):1017–1032CrossRef
5.
Zurück zum Zitat Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, Cereda D, Coluccello A, Foti G, Fumagalli R, Iotti G, Latronico N, Lorini L, Merler S, Natalini G, Piatti A, Ranieri MV, Scandroglio AM, Storti E, Cecconi M, Pesenti A, for the COVID-19 Lombardy ICU Network (2020) Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA 323:1574CrossRef Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, Cereda D, Coluccello A, Foti G, Fumagalli R, Iotti G, Latronico N, Lorini L, Merler S, Natalini G, Piatti A, Ranieri MV, Scandroglio AM, Storti E, Cecconi M, Pesenti A, for the COVID-19 Lombardy ICU Network (2020) Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA 323:1574CrossRef
6.
Zurück zum Zitat Pittman RN. Regulation of tissue oxygenation. Integrated Systems Physiology: From Molecule to Function to Disease. San Rafael (CA); 2011. Pittman RN. Regulation of tissue oxygenation. Integrated Systems Physiology: From Molecule to Function to Disease. San Rafael (CA); 2011.
7.
Zurück zum Zitat Saaby L, Poulsen TS, Hosbond S, Larsen TB, Pyndt Diederichsen AC, Hallas J, Thygesen K, Mickley H (2013) Classification of myocardial infarction: frequency and features of type 2 myocardial infarction. Am J Med 126(9):789–797CrossRef Saaby L, Poulsen TS, Hosbond S, Larsen TB, Pyndt Diederichsen AC, Hallas J, Thygesen K, Mickley H (2013) Classification of myocardial infarction: frequency and features of type 2 myocardial infarction. Am J Med 126(9):789–797CrossRef
8.
Zurück zum Zitat DeFilippis AP, Chapman AR, Mills NL (2019) Lemos JAd, Arbab-Zadeh A, Newby LK, et al. Assessment and treatment of patients with type 2 myocardial infarction and acute nonischemic myocardial injury. Circulation. 140(20):1661–1678CrossRef DeFilippis AP, Chapman AR, Mills NL (2019) Lemos JAd, Arbab-Zadeh A, Newby LK, et al. Assessment and treatment of patients with type 2 myocardial infarction and acute nonischemic myocardial injury. Circulation. 140(20):1661–1678CrossRef
9.
Zurück zum Zitat Felker GM, Adams KF, Gattis WA, O'Connor CM (2004) Anemia as a risk factor and therapeutic target in heart failure. J Am Coll Cardiol 44(5):959–966CrossRef Felker GM, Adams KF, Gattis WA, O'Connor CM (2004) Anemia as a risk factor and therapeutic target in heart failure. J Am Coll Cardiol 44(5):959–966CrossRef
10.
Zurück zum Zitat Hébert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G, Tweeddale M, Schweitzer I, Yetisir E (1999) A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. N Engl J Med 340(6):409–417CrossRef Hébert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G, Tweeddale M, Schweitzer I, Yetisir E (1999) A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. N Engl J Med 340(6):409–417CrossRef
11.
Zurück zum Zitat Fan BE, Chong VCL, Chan SSW, Lim GH, Lim KGE, Tan GB, Mucheli SS, Kuperan P, Ong KH (2020) Hematologic parameters in patients with COVID-19 infection. Am J Hematol 95(6):E131–E1E4PubMed Fan BE, Chong VCL, Chan SSW, Lim GH, Lim KGE, Tan GB, Mucheli SS, Kuperan P, Ong KH (2020) Hematologic parameters in patients with COVID-19 infection. Am J Hematol 95(6):E131–E1E4PubMed
12.
Zurück zum Zitat Weiss G, Ganz T, Goodnough LT (2019) Anemia of inflammation. Blood. 133(1):40–50CrossRef Weiss G, Ganz T, Goodnough LT (2019) Anemia of inflammation. Blood. 133(1):40–50CrossRef
13.
Zurück zum Zitat Theurl I, Mattle V, Seifert M, Mariani M, Marth C (2006) Weiss Gn. Dysregulated monocyte iron homeostasis and erythropoietin formation in patients with anemia of chronic disease. Blood. 107(10):4142–4148CrossRef Theurl I, Mattle V, Seifert M, Mariani M, Marth C (2006) Weiss Gn. Dysregulated monocyte iron homeostasis and erythropoietin formation in patients with anemia of chronic disease. Blood. 107(10):4142–4148CrossRef
14.
Zurück zum Zitat Tang N, Bai H, Chen X, Gong J, Li D, Sun Z (2020) Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 18(5):1094–1099CrossRef Tang N, Bai H, Chen X, Gong J, Li D, Sun Z (2020) Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 18(5):1094–1099CrossRef
15.
Zurück zum Zitat Tang N, Li D, Wang X, Sun Z (2020) Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 18(4):844–847CrossRef Tang N, Li D, Wang X, Sun Z (2020) Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 18(4):844–847CrossRef
16.
Zurück zum Zitat Rosenzweig JD, McThenia SS, Kaicker S (2020) SARS-CoV-2 infection in two pediatric patients with immune cytopenias: a single institution experience during the pandemic. Pediatr Blood Cancer 67(9):e28503 Rosenzweig JD, McThenia SS, Kaicker S (2020) SARS-CoV-2 infection in two pediatric patients with immune cytopenias: a single institution experience during the pandemic. Pediatr Blood Cancer 67(9):e28503
17.
Zurück zum Zitat Lazarian G, Quinquenel A, Bellal M, Siavellis J, Jacquy C, Re D, Merabet F, Mekinian A, Braun T, Damaj G, Delmer A, Cymbalista F (2020) Autoimmune haemolytic anaemia associated with COVID-19 infection. Br J Haematol 190:29–31CrossRef Lazarian G, Quinquenel A, Bellal M, Siavellis J, Jacquy C, Re D, Merabet F, Mekinian A, Braun T, Damaj G, Delmer A, Cymbalista F (2020) Autoimmune haemolytic anaemia associated with COVID-19 infection. Br J Haematol 190:29–31CrossRef
18.
Zurück zum Zitat Lopez C, Kim J, Pandey A, Huang T, DeLoughery TG (2020) Simultaneous onset of COVID-19 and autoimmune haemolytic anaemia. Br J Haematol 190:31–32CrossRef Lopez C, Kim J, Pandey A, Huang T, DeLoughery TG (2020) Simultaneous onset of COVID-19 and autoimmune haemolytic anaemia. Br J Haematol 190:31–32CrossRef
19.
Zurück zum Zitat Zagorski E, Pawar T, Rahimian S, Forman D (2020) Cold agglutinin autoimmune haemolytic anaemia associated with novel coronavirus (COVID-19). Br J Haematol 190(4):e183–e4 Zagorski E, Pawar T, Rahimian S, Forman D (2020) Cold agglutinin autoimmune haemolytic anaemia associated with novel coronavirus (COVID-19). Br J Haematol 190(4):e183–e4
20.
Zurück zum Zitat Capes A, Bailly S, Hantson P, Gerard L, Laterre P-F (2020) COVID-19 infection associated with autoimmune hemolytic anemia. Ann Hematol 99(7):1679–1680CrossRef Capes A, Bailly S, Hantson P, Gerard L, Laterre P-F (2020) COVID-19 infection associated with autoimmune hemolytic anemia. Ann Hematol 99(7):1679–1680CrossRef
21.
Zurück zum Zitat Gehrs BC, Friedberg RC (2002) Autoimmune hemolytic anemia. Am J Hematol 69(4):258–271CrossRef Gehrs BC, Friedberg RC (2002) Autoimmune hemolytic anemia. Am J Hematol 69(4):258–271CrossRef
22.
Zurück zum Zitat Alam N, Hobbelink EL, van Tienhoven AJ, van de Ven PM, Jansma EP, Nanayakkara PW (2014) The impact of the use of the early warning score (EWS) on patient outcomes: a systematic review. Resuscitation. 85(5):587–594CrossRef Alam N, Hobbelink EL, van Tienhoven AJ, van de Ven PM, Jansma EP, Nanayakkara PW (2014) The impact of the use of the early warning score (EWS) on patient outcomes: a systematic review. Resuscitation. 85(5):587–594CrossRef
23.
Zurück zum Zitat Yang X, Yang Q, Wang Y, Wu Y, Xu J, Yu Y, Shang Y (2020) Thrombocytopenia and its association with mortality in patients with COVID-19. J Thromb Haemost 18(6):1469–1472CrossRef Yang X, Yang Q, Wang Y, Wu Y, Xu J, Yu Y, Shang Y (2020) Thrombocytopenia and its association with mortality in patients with COVID-19. J Thromb Haemost 18(6):1469–1472CrossRef
24.
Zurück zum Zitat Goshua G, Pine AB, Meizlish ML, Chang CH, Zhang H, Bahel P, Baluha A, Bar N, Bona RD, Burns AJ, dela Cruz CS, Dumont A, Halene S, Hwa J, Koff J, Menninger H, Neparidze N, Price C, Siner JM, Tormey C, Rinder HM, Chun HJ, Lee AI (2020) Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. Lancet Haematol 7:e575–e582CrossRef Goshua G, Pine AB, Meizlish ML, Chang CH, Zhang H, Bahel P, Baluha A, Bar N, Bona RD, Burns AJ, dela Cruz CS, Dumont A, Halene S, Hwa J, Koff J, Menninger H, Neparidze N, Price C, Siner JM, Tormey C, Rinder HM, Chun HJ, Lee AI (2020) Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. Lancet Haematol 7:e575–e582CrossRef
25.
Zurück zum Zitat Shi J, Li Y, Zhou X, Zhang Q, Ye X, Wu Z, Jiang X, Yu H, Shao L, Ai JW, Zhang H, Xu B, Sun F, Zhang W (2020) Lactate dehydrogenase and susceptibility to deterioration of mild COVID-19 patients: a multicenter nested case-control study. BMC Med 18(1):168CrossRef Shi J, Li Y, Zhou X, Zhang Q, Ye X, Wu Z, Jiang X, Yu H, Shao L, Ai JW, Zhang H, Xu B, Sun F, Zhang W (2020) Lactate dehydrogenase and susceptibility to deterioration of mild COVID-19 patients: a multicenter nested case-control study. BMC Med 18(1):168CrossRef
26.
Zurück zum Zitat Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, HLH Across Speciality Collaboration, UK (2020) COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 395(10229):1033–1034CrossRef Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, HLH Across Speciality Collaboration, UK (2020) COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 395(10229):1033–1034CrossRef
27.
Zurück zum Zitat Tay MZ, Poh CM, Renia L, MacAry PA, Ng LFP (2020) The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol 20(6):363–374CrossRef Tay MZ, Poh CM, Renia L, MacAry PA, Ng LFP (2020) The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol 20(6):363–374CrossRef
28.
Zurück zum Zitat Cappello F (2020) Is COVID-19 a proteiform disease inducing also molecular mimicry phenomena? Cell Stress Chaperones 25(3):381–382CrossRef Cappello F (2020) Is COVID-19 a proteiform disease inducing also molecular mimicry phenomena? Cell Stress Chaperones 25(3):381–382CrossRef
29.
Zurück zum Zitat Bomhof G, Mutsaers P, Leebeek FWG, Te Boekhorst PAW, Hofland J, Croles FN et al (2020) COVID-19-associated immune thrombocytopenia. Br J Haematol 190:e61–e64CrossRef Bomhof G, Mutsaers P, Leebeek FWG, Te Boekhorst PAW, Hofland J, Croles FN et al (2020) COVID-19-associated immune thrombocytopenia. Br J Haematol 190:e61–e64CrossRef
30.
Zurück zum Zitat Toscano G, Palmerini F, Ravaglia S, Ruiz L, Invernizzi P, Cuzzoni MG, Franciotta D, Baldanti F, Daturi R, Postorino P, Cavallini A, Micieli G (2020) Guillain-Barre syndrome associated with SARS-CoV-2. N Engl J Med 382(26):2574–2576CrossRef Toscano G, Palmerini F, Ravaglia S, Ruiz L, Invernizzi P, Cuzzoni MG, Franciotta D, Baldanti F, Daturi R, Postorino P, Cavallini A, Micieli G (2020) Guillain-Barre syndrome associated with SARS-CoV-2. N Engl J Med 382(26):2574–2576CrossRef
31.
Zurück zum Zitat Cheung EW, Zachariah P, Gorelik M, Boneparth A, Kernie SG, Orange JS, Milner JD (2020) Multisystem inflammatory syndrome related to COVID-19 in previously healthy children and adolescents in New York City. JAMA. 324:294CrossRef Cheung EW, Zachariah P, Gorelik M, Boneparth A, Kernie SG, Orange JS, Milner JD (2020) Multisystem inflammatory syndrome related to COVID-19 in previously healthy children and adolescents in New York City. JAMA. 324:294CrossRef
32.
Zurück zum Zitat Angileri F, Légaré S, Marino Gammazza A, Conway de Macario E, Macario AJL, Cappello F (2020) Is molecular mimicry the culprit in the autoimmune haemolytic anaemia affecting patients with COVID-19? Br J Haematol 190(2):e92–e3 Angileri F, Légaré S, Marino Gammazza A, Conway de Macario E, Macario AJL, Cappello F (2020) Is molecular mimicry the culprit in the autoimmune haemolytic anaemia affecting patients with COVID-19? Br J Haematol 190(2):e92–e3
33.
Zurück zum Zitat Zanella A, Barcellini W (2014) Treatment of autoimmune hemolytic anemias. Haematologica. 99(10):1547–1554CrossRef Zanella A, Barcellini W (2014) Treatment of autoimmune hemolytic anemias. Haematologica. 99(10):1547–1554CrossRef
34.
Zurück zum Zitat Salama A (2015) Treatment options for primary autoimmune hemolytic anemia: a short comprehensive review. Transfus Med Hemother 42(5):294–301CrossRef Salama A (2015) Treatment options for primary autoimmune hemolytic anemia: a short comprehensive review. Transfus Med Hemother 42(5):294–301CrossRef
35.
Zurück zum Zitat Dunn JO, Mythen MG, Grocott MP (2016) Physiology of oxygen transport. BJA Educ 16(10):341–348CrossRef Dunn JO, Mythen MG, Grocott MP (2016) Physiology of oxygen transport. BJA Educ 16(10):341–348CrossRef
36.
Zurück zum Zitat Carson JL, Brooks MM, Abbott JD, Chaitman B, Kelsey SF, Triulzi DJ et al (2013) Liberal versus restrictive transfusion thresholds for patients with symptomatic coronary artery disease. Am Heart J 165(6):964–71.e1CrossRef Carson JL, Brooks MM, Abbott JD, Chaitman B, Kelsey SF, Triulzi DJ et al (2013) Liberal versus restrictive transfusion thresholds for patients with symptomatic coronary artery disease. Am Heart J 165(6):964–71.e1CrossRef
37.
Zurück zum Zitat Sabatine MS, Morrow DA, Giugliano RP, Burton PBJ, Murphy SA, McCabe CH et al (2005) Association of hemoglobin levels with clinical outcomes in acute coronary syndromes. Circulation. 111(16):2042–2049CrossRef Sabatine MS, Morrow DA, Giugliano RP, Burton PBJ, Murphy SA, McCabe CH et al (2005) Association of hemoglobin levels with clinical outcomes in acute coronary syndromes. Circulation. 111(16):2042–2049CrossRef
38.
Zurück zum Zitat Vichinsky EP, Styles LA, Colangelo LH, Wright EC, Castro O, Nickerson B (1997) Acute chest syndrome in sickle cell disease: clinical presentation and course. Cooperative Study of Sickle Cell Disease. Blood. 89(5):1787–1792CrossRef Vichinsky EP, Styles LA, Colangelo LH, Wright EC, Castro O, Nickerson B (1997) Acute chest syndrome in sickle cell disease: clinical presentation and course. Cooperative Study of Sickle Cell Disease. Blood. 89(5):1787–1792CrossRef
39.
Zurück zum Zitat Howard J (2016) Sickle cell disease: when and how to transfuse. Hematology Am Soc Hematol Educ Program 2016(1):625–631CrossRef Howard J (2016) Sickle cell disease: when and how to transfuse. Hematology Am Soc Hematol Educ Program 2016(1):625–631CrossRef
40.
Zurück zum Zitat Emre U, Miller ST, Gutierez M, Steiner P, Rao SP, Rao M (1995) Effect of transfusion in acute chest syndrome of sickle cell disease. J Pediatr 127(6):901–904CrossRef Emre U, Miller ST, Gutierez M, Steiner P, Rao SP, Rao M (1995) Effect of transfusion in acute chest syndrome of sickle cell disease. J Pediatr 127(6):901–904CrossRef
Metadaten
Titel
Prognostic significance of hemoglobin level and autoimmune hemolytic anemia in SARS-CoV-2 infection
verfasst von
Abdulrahman A. Algassim
Assem A. Elghazaly
Abdulrahman S. Alnahdi
Owais M. Mohammed-Rahim
Abdulaziz G. Alanazi
Nawaf A. Aldhuwayhi
Mashael M. Alanazi
Mohammed F. Almutairi
Ibrahim M. Aldeailej
Najeeb A. Kamli
Mahmoud D. Aljurf
Publikationsdatum
12.09.2020
Verlag
Springer Berlin Heidelberg
Schlagwort
COVID-19
Erschienen in
Annals of Hematology / Ausgabe 1/2021
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-020-04256-3

Weitere Artikel der Ausgabe 1/2021

Annals of Hematology 1/2021 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.